Research1 has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway.
Omar Abdel-WahabAndrea AblasserChristina CurtisOmar Abdel-Wahab, Andrea Ablasser, and Christina Curtis were named awardees of the 2025 Memorial Sloan Kettering Cancer Center Paul Marks Prize for Cancer Research.
